Fedora Highlights Efficacy of FPI-2119 Against Resistant Gram-Negative Bacteria at IMARI 2026

EDMONTON, Alberta — January 29, 2026. Fedora Pharmaceuticals, Inc. is presenting four posters at the inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI). The presentations summarize the mechanism, in vitro and in vivo activity, and resistance profile of FPI-2119, a first-in-class non-β-lactam antibiotic derived from lactivicin that targets penicillin-binding proteins (PBPs).

Mortality rates for invasive infections are increasing as drug-resistant strains spread. Novel classes of antibiotics, when used responsibly, offer real promise for reducing the threat of AMR. Lactivicin antibiotics were first isolated in the 1980s but were not developed. The encouraging preclinical results we are presenting at IMARI support advancing FPI-2119 into clinical trials.Christopher Micetich, CEO & Founder, Fedora Pharmaceuticals

In preclinical studies, FPI-2119 produced dose-dependent reductions in Klebsiella pneumoniae in mouse models of bacteremia and lung infection. In vitro results demonstrated potent activity against multidrug-resistant strains of K. pneumoniae, E. coli, and E. cloacae.

FPI-2119 was also shown to have potency against carbapenem-resistant strains, including P. aeruginosa and A. baumannii. When tested in vitro, FPI-2119 demonstrated 8- to 16-fold greater activity against these life-threatening infections compared with current therapeutic options.

While education and awareness about antimicrobial stewardship has improved, antimicrobial resistance continues to increase. There remains an urgent need to develop novel antibiotics. I look forward to working with Fedora as they advance FPI-2119 towards the clinic.Karen Bush, Ph.D., Indiana University professor emerita & Scientific Advisory Board member

Poster details

• Salama SM et al. In vitro activity of FPI-2119 against multidrug-resistant, carbapenem-producing Gram-negative pathogens (Abstract 67528)
• Bush K, et al. FPI-2119 bactericidal activity and resistance selection in Enterobacterales (Abstract 69798)
• Miesel L, et al. In vitro activity of FPI-2119 against Klebsiella pneumoniae in murine septicemia and lung infection models (Abstract 70939)
• Sayed ARM, et al. PBP binding patterns and morphological changes in response to FPI-2119 (Abstract 71137)